All Outputs (3)

Development of PDT/PET theranostics: synthesis and biological evaluation of an ¹⁸F-radiolabeled water soluble porphyrin (2015)
Journal Article
Entract, G. M., Bryden, F., Domarkas, J., Savoie, H., Allott, L., Archibald, S. J., …Boyle, R. W. (2015). Development of PDT/PET theranostics: synthesis and biological evaluation of an ¹⁸F-radiolabeled water soluble porphyrin. Molecular pharmaceutics, 12(12), 4414-4423. https://doi.org/10.1021/acs.molpharmaceut.5b00606

Synthesis of the first water-soluble porphyrin radiolabeled with fluorine-18 is described: a new molecular theranostic agent which integrates the therapeutic selectivity of photodynamic therapy (PDT) with the imaging efficacy of positron emission tom... Read More about Development of PDT/PET theranostics: synthesis and biological evaluation of an ¹⁸F-radiolabeled water soluble porphyrin.

Evaluation of configurationally restricted copper-64 labelled bis tetraazamacrocyclic as potential PET agents for CXCR4 expression in oncology imaging (2015)
Journal Article
Clemente, G. S., Burke, B. P., Nigam, S., Cawthorne, C., & Archibald, S. J. (2015). Evaluation of configurationally restricted copper-64 labelled bis tetraazamacrocyclic as potential PET agents for CXCR4 expression in oncology imaging. European journal of nuclear medicine and molecular imaging, 42(S1), S42. https://doi.org/10.1007/s00259-015-3198-z

Conference abstract

New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities (2015)
Journal Article
Poty, S., Désogère, P., Goze, C., Boschetti, F., D‘huys, T., Schols, D., …Denat, F. (2015). New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities. Dalton Transactions : an international journal of inorganic chemistry, 44(11), 5004-5016. https://doi.org/10.1039/c4dt02972k

CXCR4 is a target of growing interest for the development of new therapeutic drugs and imaging agents as its role in multiple disease states has been demonstrated. AMD3100, a CXCR4 chemokine receptor antagonist that is in current clinical use as a ha... Read More about New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities.